Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Polyps 1Fatigue 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 900Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × eicosapentaenoic acid ethyl ester × Clear all
NCT03661047 2021-11-17

OMICC

Massachusetts General Hospital

Phase 2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Polyps, Colorectal Neoplasms

NCT02940223 2021-06-10

Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
2 enrolled 6 charts

Fatigue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡